LA JOLLA, CA-The Salk Institute for Biological Studies today announced the establishment of the Renato Dulbecco Chair in Genomics and the Roger Guillemin Chair in Neuroscience based on an endowment of $6 million from Irwin Jacobs, chairman of the Salk's Board of Trustees, and his wife Joan Klein Jacobs.
"The creation of each chair will pay permanent tribute to the extraordinary research contributions of these two remarkable scientists," said Salk President William R. Brody. "The central roles played by Dr. Dulbecco in genomics and Dr. Guillemin in neuroscience have built a legacy of leadership and innovation that will remain embedded in the Institute now and for years to come."
Renato Dulbecco, M.D., a Founding Fellow of the Salk Institute and President Emeritus, conducted seminal research that provided the first clue to the genetic nature of cancer. He was jointly awarded the 1975 Nobel Prize in Physiology or Medicine for discoveries concerning the interaction between tumor viruses and the genetic material of the cell. In his studies, he described how a virus could insert its own genes into the chromosome of the cell it infects and "turn on" the uncontrolled growth that is the hallmark of cancer. This was the first solid evidence that cancer originates when a cell's genes become mutated, or co-opted, and the breakthrough transformed the way researchers viewed cancer. In 1986, Dulbecco initiated the idea of studying all human genes, helping to launch the worldwide Human Genome Project.
Dr. Dulbecco is the recipient of numerous awards and honors, including the Lasker Award and those given by the National Academy of Sciences, the Royal Society of London and the Academia Del Lincei of Italy. To highlight his achievements, the Salk Institute established the Dulbecco Laboratories for Cancer Research in 2005.
Roger Guillemin, M.D., Ph.D., a distinguished professor and former president of the Salk Institute, won the Nobel Pr
|Contact: Kat Kearney|